National Health Research Institutes (NHRI) and Taivex Therapeutics Corp (Taivex) have signed the technology transfer agreement in September, 2021. Taivex has granted the exclusive rights of the small molecule Mertansine conjugate, T-1501, with global patents.

About DBPR186
Phospholipid phosphatidylserine (PS), abundant on the external surfaces of cancer cells, is an established target molecule for cancer therapy. T-1501 is a developmental drug candidate for delivering therapeutic agent, DM-1, that associates with PS.